FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321785631> ?p ?o ?g. }

• W4321785631 abstract "Background: It has been shown that drugs used parenterally cause errors in immunosuppressant concentrations measured by LC-MS / MS method. It is yet unknown whether this measurement error is due to drug-drug interaction or analytical interference. Objective: The aim of this study is to investigate the possible interaction and inhibition concentrations of broad-spectrum antibiotics (ertapenem, meropenem, imipenem) with 4 different immunosuppressants (tacrolimus, sirolimus, everolimus, cyclosporine A) by molecular docking. objective: The aim of this study is to investigate the possible interaction and inhibition concentrations of broad-spectrum antibiotics (ertapenem, meropenem, Imipenem) with 4 different immunosuppressants (tacrolimus, sirolimus, everolimus, cyclosporine A) by molecular docking. Method: The docking results of ertapenem, meropenem, and imipenem-cilastatin drugs, which are frequently used in intensive care units and wards, were analyzed with the Autodock 4.2 program. Binding energy levels and inhibition concentrations were recorded. method: The docking results of ertapenem, meropenem and imipenem-cilastatin drugs, which are frequently used in intensive care units and wards, were analyzed with the Autodock 4.2 program. Binding energy levels and inhibition concentrations were recorded. Results: The highest binding energies of the most stable conformations, providing the best compatibility among the active ingredients, belong to cilastatin. The interaction energy of cilastatin with sirolimus in 320 conformations was calculated as -4.08 kcal/mol. Sirolimus interacted with ertapenem at -3.43, imipenem at -2.53, and meropenem at -3.84 kcal/mol. According to these values, the receptor, which is the most compatible host with all ligand molecules, is sirolimus. The least interaction energy value was calculated between cyclosporine and imipenem (-1.12 kcal / mol). result: The highest binding energies of the most stable conformations, providing the best compatibility among the active ingredients, belong to cilastatin. The interaction energy of cilastatin with sirolimus in 320 conformations was calculated as -4.08 kcal/mol. Sirolimus interacted with ertapenem at -3.43, with imipenem at -2.53, and with meropenem at -3.84 kcal/mol. According to these values, the receptor, which is the most compatible host with all ligand molecules, is sirolimus. The least interaction energy value was calculated between cyclosporine and imipenem (-1.12 kcal / mol). Conclusion: Concerning the most stable conformations of models docked with Autodock tools, it has been determined that carbapenems interact with immunosuppressants. Since the detected inhibition concentration levels can be seen in blood samples taken immediately after carbapenem injection, immunosuppressant measurement is recommended before the use of carbapenem in immunosuppressant monitoring of transplant patients. conclusion: From the appearance of the most stable conformations of models docked with Autodock tools, it has been determined that carbapenems interact with immunosuppressants. Since the detected inhibition concentration levels can be seen in blood samples taken immediately after carbapenem injection, immunosuppressant measurement is recommended before the use of carbapenem in immunosuppressant monitoring of transplant patients." @default.
• W4321785631 created "2023-02-25" @default.
• W4321785631 creator A5009221533 @default.
• W4321785631 creator A5020307342 @default.
• W4321785631 creator A5035792717 @default.
• W4321785631 creator A5039432519 @default.
• W4321785631 creator A5067064352 @default.
• W4321785631 creator A5074988328 @default.
• W4321785631 creator A5085388960 @default.
• W4321785631 creator A5086453425 @default.
• W4321785631 date "2023-02-24" @default.
• W4321785631 modified "2023-10-02" @default.
• W4321785631 title "Demonstration of Interaction Between Carbapenem Group Antibiotics and Different Immunosuppressant Drugs by Molecular Docking" @default.
• W4321785631 doi "https://doi.org/10.2174/1570180820666230224104658" @default.
• W4321785631 hasPublicationYear "2023" @default.
• W4321785631 type Work @default.
• W4321785631 citedByCount "0" @default.
• W4321785631 crossrefType "journal-article" @default.
• W4321785631 hasAuthorship W4321785631A5009221533 @default.
• W4321785631 hasAuthorship W4321785631A5020307342 @default.
• W4321785631 hasAuthorship W4321785631A5035792717 @default.
• W4321785631 hasAuthorship W4321785631A5039432519 @default.
• W4321785631 hasAuthorship W4321785631A5067064352 @default.
• W4321785631 hasAuthorship W4321785631A5074988328 @default.
• W4321785631 hasAuthorship W4321785631A5085388960 @default.
• W4321785631 hasAuthorship W4321785631A5086453425 @default.
• W4321785631 hasConcept C104317684 @default.
• W4321785631 hasConcept C159110408 @default.
• W4321785631 hasConcept C185592680 @default.
• W4321785631 hasConcept C2775905019 @default.
• W4321785631 hasConcept C2777437143 @default.
• W4321785631 hasConcept C2778368673 @default.
• W4321785631 hasConcept C2779375183 @default.
• W4321785631 hasConcept C2779631663 @default.
• W4321785631 hasConcept C2780152424 @default.
• W4321785631 hasConcept C41685203 @default.
• W4321785631 hasConcept C501593827 @default.
• W4321785631 hasConcept C55493867 @default.
• W4321785631 hasConcept C71924100 @default.
• W4321785631 hasConcept C94665300 @default.
• W4321785631 hasConcept C98274493 @default.
• W4321785631 hasConceptScore W4321785631C104317684 @default.
• W4321785631 hasConceptScore W4321785631C159110408 @default.
• W4321785631 hasConceptScore W4321785631C185592680 @default.
• W4321785631 hasConceptScore W4321785631C2775905019 @default.
• W4321785631 hasConceptScore W4321785631C2777437143 @default.
• W4321785631 hasConceptScore W4321785631C2778368673 @default.
• W4321785631 hasConceptScore W4321785631C2779375183 @default.
• W4321785631 hasConceptScore W4321785631C2779631663 @default.
• W4321785631 hasConceptScore W4321785631C2780152424 @default.
• W4321785631 hasConceptScore W4321785631C41685203 @default.
• W4321785631 hasConceptScore W4321785631C501593827 @default.
• W4321785631 hasConceptScore W4321785631C55493867 @default.
• W4321785631 hasConceptScore W4321785631C71924100 @default.
• W4321785631 hasConceptScore W4321785631C94665300 @default.
• W4321785631 hasConceptScore W4321785631C98274493 @default.
• W4321785631 hasLocation W43217856311 @default.
• W4321785631 hasOpenAccess W4321785631 @default.
• W4321785631 hasPrimaryLocation W43217856311 @default.
• W4321785631 hasRelatedWork W2051830798 @default.
• W4321785631 hasRelatedWork W2086393652 @default.
• W4321785631 hasRelatedWork W2132068732 @default.
• W4321785631 hasRelatedWork W2145445190 @default.
• W4321785631 hasRelatedWork W2156269036 @default.
• W4321785631 hasRelatedWork W2285087135 @default.
• W4321785631 hasRelatedWork W2426518104 @default.
• W4321785631 hasRelatedWork W2531723341 @default.
• W4321785631 hasRelatedWork W31212056 @default.
• W4321785631 hasRelatedWork W4321785631 @default.
• W4321785631 hasVolume "20" @default.
• W4321785631 isParatext "false" @default.
• W4321785631 isRetracted "false" @default.
• W4321785631 workType "article" @default.